Am J Kidney Dis: the official journal of the National Kidney Foundation
Perfect Bars bring together whole food protein and 20+ superfoods in a convenient bar

decreased TSH, decreased Total T4, and decreased Free T4) Uncommon (0.1% to 1%): Galactorrhea, hypoadrenalism, diabetes insipidus [Ref] Local Very common (10% or more): Injection site pain (13.8%), injection site reactions Common (1% to 10%): Injection site hematoma [Ref] Dermatologic Very common (10% or more): Alopecia (13.2%) Common (1% to 10%): Pruritus, bruise, rash Uncommon (0.1% to 1%): Cellulitis, petechiae, urticaria, basal cell carcinoma [Ref] Musculoskeletal Common (1% to 10%): Joint pain, backache Uncommon (0.1% to 1%): Arthritis, joint effusion, muscle pain, Raynaud's phenomenon [Ref] Psychiatric Common (1% to 10%): Depression Uncommon (0.1% to 1%): Anxiety, paranoia, libido decrease [Ref] Other Very common (10% or more): Fatigue (31.8%), generalized pain (15%) Common (1% to 10%): Weakness Uncommon (0.1% to 1%): Hearing loss, otitis [Ref] Respiratory Very common (10% or more): Upper respiratory tract infection (18.2%), sinusitis (12%) Common (1% to 10%): Cold symptoms, flu symptoms, epistaxis Uncommon (0.1% to 1%): Pneumonia, pulmonary nodule, status asthmaticus [Ref] Renal Uncommon (0.1% to 1%): Increased creatinine kinase [Ref] Hypersensitivity Uncommon (0.1% to 1%): Allergic reaction Frequency not reported : Anaphylactic reaction [Ref] Immunologic Very common (10% or more): Antibodies to octreotide (25%) Ocular Common (1% to 10%): Blurred vision, visual disturbance Uncommon (0.1% to 1%): Increased intraocular pressure [Ref] Genitourinary Common (1% to 10%): Urinary tract infection, pollakiuria Uncommon (0.1% to 1%): Gynecomastia, amenorrhea, polymenorrhea, oligomenorrhea, vaginitis, nephrolithiasis, hematuria [Ref] References 1

Melanotan II stimulates melanin receptors in the brain, which helps increase libido and improve sexual function, making it an effective treatment for sexual dysfunction, erectile dysfunction, and decreased libido
The expanded access segment is expected to grow at a CAGR of 8.20% during the forecast period